Lilly manufacturing reinspections
Executive Summary
FDA has begun reinspecting Lilly's manufacturing facilities for the antidepressant Cymbalta and intramuscular antipsychotic Zyprexa IM. "The reinspections began in early May 2003," Lilly says in its 10-Q filed with the Securities & Exchange Commission May 8. FDA arrived in Indianapolis May 5. The company told investors April 22 that Cymbalta's (duloxetine) fill-finish facility was ready for reinspection, while Zyprexa IM (olanzapine) would be ready for reinspection later this year (1"The Pink Sheet" April 28, p. 31)...
You may also be interested in...
Lilly GMPs Will Not Deter Product Rollout, Firm Says
The remaining Lilly products delayed by good manufacturing practices compliance problems could be approved by FDA before the company has fully implemented its GMP improvement program
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.